Digna Biotech Overview
- Founded
- 2003
- Status
- Out of Business
- Employees
- 11
- Latest Deal Type
- Out of Business
Digna Biotech General Information
Description
Developer of therapeutic and diagnostic products designed to offer treatment of acute hospital cases. The company's therapeutic and diagnostic products leverages world-class scientific and clinical expertise to turn early-stage medical innovations into clinical-stage partnering candidates for further development and subsequent commercialization.
Contact Information
Primary Industry
Diagnostic Equipment
Other Industries
Biotechnology
Primary Office
- Avda. Pio XII, 22
- Oficina 2
- 31008 Pamplona
- Spain
+34 948 00 00 00
Digna Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Out of Business | 01-Jul-2016 | 00.000 | Completed | Out of Business | ||
| 3. Grant | 03-Feb-2011 | 00000 | 00.000 | Completed | Generating Revenue | |
| 2. Early Stage VC | 26-Sep-2008 | $4.32M | $4.32M | Completed | Startup | |
| 1. Early Stage VC | 23-Oct-2007 | Completed | Startup |
Digna Biotech Patents
Digna Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-2742948-A1 | Use of cardiotrophin-1 for the treatment of kidney diseases | Withdrawn | 10-Aug-2011 | 000000000 | |
| JP-2014522879-A | Use of cardiotrophin-1 for the treatment of kidney disease | Pending | 10-Aug-2011 | 000000000 | 0 |
| CA-2844792-A1 | Use of cardiotrophin-1 for the treatment of kidney diseases | Abandoned | 10-Aug-2011 | 000000000 | |
| AU-2012293574-A1 | Use of cardiotrophin-1 for the treatment of kidney diseases | Abandoned | 10-Aug-2011 | 000000000 | |
| US-20140170125-A1 | Use of cardiotrophin-1 for the treatment of kidney diseases | Abandoned | 10-Aug-2011 | A61K38/22 |
Digna Biotech Executive Team (6)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Jesus Hernandez Ph.D | Chief Executive Officer |
Digna Biotech Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialDigna Biotech Investments (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 | 19-Sep-2012 | 00000 0000 | 00.00 | Drug Discovery | |
| Hepacyl Therapeutics | 01-May-2010 | Platform Creation | Biotechnology | 00000 000 |
Digna Biotech Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 0000000 0000000000 | 01-May-2010 | 00000000 00000000 | Completed |
|